PHARMACEUTICAL FACULTY MEDICAL UNIVERSITY – SOFIA

2, Dunav Street, 1000 Sofia; Tel./Fax: 02 9879 874; e-mail: dean@pharmfac.mu-sofia.bg

Preclinical and clinical expert report for efficiency and safety of nutrient additive MAOLO on the hemopiesis in patients with oncological diseases, undergoing chemotherapy.

Preclinical expert report for safety of the nutrient additive MAOLO

The preclinical safety data are based on an experimental study of nutrient additive MAOLO in Department "Pharmacology, pharmacotherapy and toxicology" of Pharmaceutical faculty of the Medical University – Sofia. The nutrient additive has been studied for acute toxicity on laboratory animals – male and female mice and for cytotoxicity on human cellular line (HT-29). The studied product has been introduced once perorally in doses 5000 mg/kg and 10 000 mg/kg body mass (b.m.) of 36 male and female mice, line H. The introduction is peroral since this is the way of applying the nutrient additives in people. Every animal has been observed for 14 days for change in the general condition and lethal outcome. It has been found that the LD50 dose (the dose causing the death of 50% of the test animals) in MAOLO is more than 10 000 mg/kg b.m. As per the classification of Hodge and Sterner (Hodge H.C. & Sterner J.H., (1943). Determination of substance acute toxicity by LD50. Am. Ind. Hyg. Assoc. 10: 93-96) this value applies to class V, i.e. to the group of practically non-toxic substances. For cytotoxicity study, the nutrient additive MAOLO has been applied in in vitro model of human intestinal epithelium (cellular line HT-29). The results display that MAOLO is non-toxic in terms of this human cellular line, even when applying supraphysiological concentrations. A conclusion has been made that the product submitted –nutrient additive MAOLO is practically non-toxic in peroral application on male and female white mice and shows no toxicity in in vitro model of human intestinal epithelium (cellular line HT-29).

Clinical expert report for efficiency and safety of the nutrient additive MAOLO

The efficiency of MAOLO in clinical conditions has been tested in total of 8 specialized oncological units in 7 cities in Bulgaria. The first observations of MAOLO capsules date back to August 2009 and the last ones have ended in January 2019. The nutrient additive MAOLO has been applied in total of 9 of the most frequent oncological diseases in Bulgaria. These are solid tumors, affecting the lungs, mammal gland, uterine cervix, colon and rectum, pancreas as well as malignant hematological diseases - non-Hodgkin lymphoma, Hodgkin disease, lymphoplasmocyte lymphoma. The nutrient additive has been applied in total of 559 hospitalized and ambulatory patients. The effect of MAOLO on the hematological indicators mainly affected by the chemotherapy has been clinically and laboratory established - leucocytes, thrombocytes, hemoglobin. The daily dose, applied in these investigations varies from 1 capsule to 6 capsule (maximal dose) depending on the hematological indicators. The capsules MAOLO have been taken during or after feeding. The effect of the nutrient additive has been traced for a period of 7-15 days to more than 1 year in the various clinical observations. The applied initial dose varies between the various centers - 1 capsule, 2x1, 3x1, 3x2 capsules a day. If needed, the dose has been increased with 1-2 capsules for 24 hours to the maximal dose of 6 capsules a day. The normalization of the leucocytes after the applying of dose 1 capsule a day is reported slowly – hardly after a 10 days treatment.

After the performing of the chemotherapy, a need was declared to apply the nutrient additive MAOLO in the maximal dose of 3x2 capsules with duration of minimum 10-20 days for increase of the values of the thrombocytes, neutrophils and hemoglobin. As a prevention, during the whole time of the cytostatic treatment, 1-2 capsules a days were applied.

As an effect of the intake of the nutrient additive on the hemopoiesis, normalized hemoindicators were found or values reached which do not require the applying of other measures for improvement of the hemo indicators. If the target values have not been reached with the lower doses of the nutrient additive MAOLO, a maximal dose of $3x^2$ capsules a day was applied.

After correction of the dose, values of the hemo-indicators have been reached which allow the performing of chemotherapy with no delay. No delay of the chemotherapy was required due to fall below the limit of leucocytes, thrombocytes and hemoglobin. MAOLO has a good leucostimulating effect in light and moderately heavy leucopenia and stabilization with trend to increase of the thrombocytes and neutrophils. The observed patients of various centers have had original values of the leucocytes between 1,5 and 3,2.10^9/L. the level of leucocytes is traced in a controlled manner within intervals of 7-10 days, usually between two infusions of the cytostatics. The leucocytes have increased above the referent 3,5.10^9/L in 5-7 days, in individual cases up to 10 days. In the prophylactic intake of 1-2 capsules a day, throughout the cytostatic treatment, the values of the leucocytes have reached to5-6.10^9/L, in individual cases more but within the referent limits. In ambulatory patients, whereat the leucocytes have been traced once a week, the leucocytes have stabilized above 3,5 g/L, at original values 1,8-2,9.10^9/L. And in this group of patients, the leucocytes have normalized reaching 4-5.10^9/L.

The last clinical observation of nutrient additive MAOLO has been performed in Complex Oncological Center – Ruse for a period of 4 months – from October 2018 to January 2019 of total of 39 patients. In this treatment, the effects of MAOLO have been compared to a control product with random signature SGN which has a composition and form enabling a comparative study with MAOLO. This enables the comparison to a similar product which has also been used in the same dose as MAOLO – 3x 2 capsules a day. This comparison is important since it enables to make a comparative conclusion regarding the effect of the two products on the hematological indicators and the need to use further measures for their stimulation. It also makes impression that in some of the patients taking SGN, the intake of MAOLO was necessitated. For patients who continued with the intake of SGN, no positive impact was reported of the hematological indicators. Besides, it has been evaluated that for these patients, the risk for complications as a result of induced bone marrow toxicity remained increased which may necessitate interruption of the chemotherapeutic treatment. In table 1, a comparison has been presented between MAOLO and SGN based on the observations.

performing the observation number of patients and period observation number of patients and period observation number of patients and period Normalized hemo-indicators or values reached which do not require the application of other measures for improvement of the hemo-indicators and continued Nor delayed and continued within schedule Nortalized hemo-indicators Normalized hemo-indicators Normalized hemo-indicators and continued within schedule Normalized hemo-indicators Nor delayed and continued within schedule Normalized for 4 carcinoma 17 patients for 4 carcinoma Initial dose - 3x1 capsule during reading indicators - carcinoma Normalized for the hemo- indicators Normalized for the hemo- indicators Normalized for the hemo- indicators Normalized for the hemo- indicators Complex for 4 conclosed for 4 carcinoma Colorectal for 4 carcinoma 8 of SQN to bold and proceeded vithin schedule. After replacement of SQN with MAOLO to the hemonoherapy<	Place of	Tota	l O	cological	Number	U U	and duration of		Laboratory		the laboratory tests	Result on the
observation observation patients observation patien						-		-		the habor atory tests		
Image: complex one observation Prior of observation Complex one observation Normalized hemo-indicators or values of non trequire the applications of other measures for improvement of the hemo-indicators or values of the chemotherapy. The dose has been which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo-indicators were reached which do not require the application of the measures for improvement of the hemo-indicators were reached which do not require the application of the measures for improvement of the hemo-indicators were reached which do not												F J
Omplex oncological center (COC)- Ruse-RCON Dr. Valerial Yordanov 17 patients for center Vordanov Colorectal momba - log land log land carcinoma 11 patient, log land carcinoma For 7 patients for 7 patients per log land carcinoma Normalized hemo-indicators or values per log land carcinoma Not delayed and continued per log land per log land per log land per log land carcinoma Not delayed land continued per log land per lo		1	-		I							
oncological center (COC)- Ruse-BODD Dr. Ivani Vanova Dr. Valerii Yordanov 4 months - 10,11,12 2018 and 0.12.019 carcinoma tan integration carcinoma and continued reached which do not require the application of other measures for improvement of the hemo-indicators hemoglobin and continued application of other measures for improvement of the hemo-indicators Not delayed and continued within schedule Dr. Valerii Yordanov Improvement of the hemo-indicators Not delayed and continued within schedule Not delayed and continued within schedule To reached which do not require the application of other carcinoma 1 Initially 3x1 capsule during feeding; in 5 of the patients after chemotherapy, the dose has been increased to 3x2 After dose correction, values of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo- indicators Not delayed and continued within object Complex (COC) 17 patients for 4 months - (2018 and Carcinoma In 1 patients Server S of SGN in 1 patients replacement was needed of SGN with after the monobyeiss in 1 patients for dar gland carcinoma S of SGN in 1 patients feeding in 1 patients in 1 patients in 1 patients in 1 patients in 1 patients in 2 pa												
center (ČOC)- Ruse-EOOD Dr. Valerii Yordanov 10,11,12 2018 and 01.2019 10,11,12 2018 and 01.2019 Imitial y 3.1 capsule during feeding, in 5 of the patients after chemotherapy, the dose has been increased to 3x2 application of other measures for improvement of the hemo-indicators Not delayed Vralerii Yordanov Not delayed Mammal gland 1 Initial dose -3x1 capsule during feeding; after performed chemotherapy, the dose has been increased to 3x2 After dose correction, values of the measures for improvement of the hemo- indicators Not delayed Complex oncological center (COC)- 10,11,12 17 patients months - centron Complex 01,2019 17 patients the dose for solution S of SGN in 1 patient, replacement was needed of SGN with after the chemotherapy twith obclas Not delayed Mammal gland 17 patients centron (COC)- 2012,019 Complex indicators - replacement was needed of SGN with in 1 patient, replacement was needed of SGN with in 1 patients centron (COC)- 2013,019 17 patients to bone marrow toxicity registered after the chemotherapy toxicity registered in 5 patients replacement was needed of SGN with in 5 patients 3x2 capsules during replacement was needed of SGN with in 1 patient, the tested hemo-indicators were indicators The chemotherapy after replacement with AOLO.0 (xz), due to bone marrow toxicity registered indicators Mammal gland carcinoma 9 patients to bone marrow toxicity after chemo	Complex	39 patier	39 patients for Col		11	For 7 patie	For 7 patients – 3x2 capsules		Hemo-	Normalized hemo-indicators or values		Not delayed
Ruse-EOOD Dr. Valerii Yordanov and 01.2019 and 01.2019 and 01.2019 Image: Construction of the construction of the patients offer increased to 3x2 thrombocytes, hemoglobin improvement of the hemo-indicators schedule Dr. Valerii Yordanov Image: Construction of the hemo-indicators Image: Construction of the hemo-indicators Not delayed and continued on the patients offer reaction of the hemo-indicators Not delayed and continued on the patients of the hemo-indicators were reached which do indicators Not delayed and continued on the patients of the hemo-indicators were reached which do indicators Not delayed and continued on the patients of the hemo-indicators were reached which allowed the performing of chemotherapy with no delay Complex Complex Complex Complex Complex Ruse- EOOD Dr. Na Valerii Yordanov 17 patients for 4 months - (COC)- 01.1.12 Colorectal for 4 months - (COC)- 01.1.21 Ro f SON in 1 patients carcinoma So f SON in 1 patients carcinoma 3x2 indicators - indicators - theroglobin indicators - theroglobin indicators - hemoglobin In 7 of the patients SON did not cassentially affect the hemopoisis After replacement of SON with MAOLO in 1 patients bave been normalized The chemotherapy after replacement with MAOLO was not delayed and proceeded of SON with after the tested hemo-indicators have been normalized Mammal EODD Dr. Valerii Yordanov 9 patients in a patients in a patients carcinoma 3x2 in patients in a patients carcinoma Sx2 in patients in a patients in the chemotherapy after replacement with MAOLO accontinued within schedule. Mammal gland in t patients carcinoma 9 patie	oncological		4 months – car			(maximal dose) MAOLO during					and continued	
Dr. Ivalerii Yordanov Lung T Initially 3x1 capsule during feeding, in 5 of the patients after chemotherapy, the dose has been increased to 3x2 hemoglobin After dose correction, values of the hemo-indicators were reached which do not require the application of other measures for improvement of the hemo- indicators Not delayed and continued within schedule Mammal gland (cercinoma 4 Initial Usar Jackson (carcinoma 10 fill all di carcinoma Not delayed and continued within schedule Complex (CCC)- 17 patients for 4 (CCC)- Colorectal carcinoma 8 of SGN in 1 patient, carcinoma 3x2 during feeding, feeding, schedule In 7 of the patients SGN did no to bone marrow toxicity registered after the cancinoma In 7 of the patients indicators - leucocytes, hemoglobin In 7 of the patients SGN did not in 1 patient, to bone marrow toxicity registered after the chemotherapy The chemotherapy after replacement with MAOLO (3x2c) due to bone marrow toxicity registered after the carcinoma Six2 (carcinoma In 7 of the patients with SGN, the hemo-indicators The chemotherapy after replacement with AOLO continued within schedule. After intake of SGN with MAOLO (3x2c) due to bone marrow toxicity registered after the chemotherapy Six2 (carcinoma In 1 patient, feeding thrombocyces, hemoglobin In 1 patient, the leucocytes, hemoglobin In 1 patient, the tested beno-indicators were reached which allowed the performing of chemotherapy with no delayed but the risk for complications remained heigh as a result of bone marrow toxicity induced by the chemotherapy Mammal (gland (carcinoma 9 patients to bone marrow toxicity afte							feeding					
Dr. Valerii Yordanov Lung Vordanov Lung carcinoma 7 r Initially 3X1 capsule during feeding; in 5 of the patients after chemotherapy, the dose has been increased to 3x2 After dose correction, values of the hemo-indicators were reached which do not require the applications of other measures for improvement of the hemo- indicators Not delayed within schedule Mammal carcinoma 4 gland carcinoma Initial dose – 3x1 capsule during feeding; after performing oc was necessitated After dose correction, values of the hemo-indicators were reached which allowed the performing of chemotherapy with no delay Not delayed Complex oncological center (CCOC)- to 10.11,12 17 patients carcinoma Colorectal N 1 patient, replacement was capsules 8 of SON during feeding 3x2 feeding Hemo- indicators – themoglobin The chemotherapy matrix allowed the performing of chemotherapy with no delay The chemotherapy after replacement with MAOLO in 1 patient, replacement was needed of SGN with feeding Sx2 feeding Hemo- to bone marrow toxicity registered after the carcinoma The chemotherapy after replacement with MAOLO in 1 patient, toxicity registered after the carcinoma For the patients with SGN, the hemopolesis is not essentially affect the patients the hemoglobin have been normalized The chemotherapy after replacement with MAOLO continued within schedule. Valarii Yordanov Mammal gland Is patients to bone marrow toxicity after chemotherapy Sx2 feeding For the patients with SGN, the hemopolesis is not essentially affect the for 3 patients the hemoglobin, the leuoceyctes ar also below the lower limit. The che			ıd 01.2019							improvement of	the hemo-indicators	schedule
Yordanov Anterinantial for the participant of the participa		ov	Lur		7	Initially	x1 concula durin	α	hemoglobin	After dose corr	action values of the	Not delayed
Considered in the second of the second o					/							
Image: base base base base base base base base	Yordanov			aemonia								
Image: bit with the second of the												
Image: constraint of the second se			gland									
Image: Construct of the					4	Initial dose	– 3x1 capsule du	ring	_	After dose corr	ection, values of the	Not delayed
Complex oncological center 17 patients months - (COC)- Colorectal and carcinoma 8 of SGN In 1 patient, replacement was needed of SGN with during 3x2 feeding Hemo- capsules during In 7 of the patients capsules In 7 of the patients capsules SGN did not essentially affect the hemopoiesis in 1 patient, the tested hemo-indicators have been normalized The chemotherapy after replacement with MAOLO proceeded within schedule. After intake of SGN he chemotherapy was not delayed and proceeded within schedule. After intake of SGN he chemotherapy was not delayed but the risk for complications remained high as a result of bone marrow toxicity registered after the gland Mammal In 5 patients replacement was needed of SGN with MAOLO 3x2c due to bone marrow chemotherapy 3x2 capsules during feeding For the patients with SGN, the hemoglobin have been normalized The chemotherapy after replacement with MAOLO complications remained high as a result of bone marrow toxicity induced by the chemotherapy Mammal Yordanov 9 patients replacement was needed of SGN with MAOLO 3x2c due to bone marrow toxicity after chemotherapy 3x2 capsules during feeding For the patients with SGN, the hemopoiesis is not essentially affected For 3 patients the hemoglobin, the leucocytes are also below the lower limit. The chemotherapy after replacement with MAOLO continued within schedule. MAOLO 3x2c due to bone marrow toxicity after chemotherapy For the patients with SGN, the hemopoiesis is not essentially affected For 3 patients the hemoglobin, the leucocytes are also below the lower limit. The chemotherapy after replacement with MAOLO continued within schedule. MAOLO 3x2c due to bone marrow For the patie												
Summary of the results for the product SGN Complex oncological center (COC)- (COC)- (COC)- (D.11,12 Colorectal carcinoma 8 of SGN In 1 patient, replacement was needed of SGN with Dr. Valerii 3x2 (COC)- To, 10,11,12 Hemo- indicators – leucocytes, thrombocytes, to bone marrow toxicity registered after the chemotherapy Hemo- indicators – leucocytes, thrombocytes, hemoglobin In 7 of the patients SGN did not essentially affect the hemopoiesis After replacement of SGN with MAOLO in 1 patient, the tested hemo-indicators have been normalized The chemotherapy was not delayed and proceeded within schedule. After intake of SGN he chemotherapy was not delayed but the risk for complications remained high as a result of bone marrow toxicity induced by the chemotherapy Wardanov Mammal gland carcinoma 9 patients replacement was needed of SGN with MAOLO 3x2c due to bone marrow toxicity after chemotherapy 3x2 diverse after the chemotherapy The chemotherapy after replacement with MAOLO continued within schedule. Mammal gland carcinoma 9 patients to bone marrow toxicity after chemotherapy 3x2 during feeding to bone marrow toxicity after chemotherapy The chemotherapy after replacement with MAOLO continued within schedule. Mather replacement was needed of SGN with the low classed but the lower toxicity after chemotherapy The chemotherapy after replacement with MAOLO continued within schedule. Mather replacement of SGN with MAOLO, the hemo-indicators were The chemotherapy after replacement with MAOLO continued within schedule.			carcinoma									
Complex oncological center17 patients for 4 months - (COC)-Colorectal for 4 months - (2012)8 of SGN in 1 patient, replacement was needed of SGN with feeding3x2 capsules during feedingHemo- indicators - leucocytes, thrombocytes, hemoglobinIn 7 of the patients SGN did not essentially affect the hemopoiesis After replacement of SGN with MAOLO in 1 patient, the tested hemo-indicators have been normalizedThe chemotherapy after replacement with MAOLO was not delayed and proceeded within schedule. After intake of SGN he chemotherapy was not delayed but the risk for complications remained high as a result of bone marrow toxicity registered after the chemotherapyMammal gland9 patients replacement was needed of SGN with feeding3x2 hemoglobinHemo- indicators - hemoglobinIn 7 of the patients SGN did not essentially affect the hemopoiesis in 1 patient, the tested hemo-indicators have been normalizedThe chemotherapy after replacement with MAOLO or complications remained high as a result of bone marrow toxicity induced by the chemotherapyVordanovMammal gland9 patients to bone marrow toxicity after replacement was needed of SGN with during feeding3x2 feedingFor the patients with SGN, the hemoglobin fell below the lower limitThe chemotherapy after replacement with MAOLO continued within schedule.VordanovMammal gland9 patients after the chemotherapy3x2 capsulesFor the patients with SGN, the the lower limitThe chemotherapy even not delayed, increased the risk for complications due to bone marrow toxicity after ch											no delay	
oncological centerfor 4 months - (COC)-carcinomaIn 1 patient, replacement was needed of SGN with feedingcapsules during feedingindicators - leucocytes, thrombocytes, have been normalizedwith MAOLO was not delayed and proceeded within schedule. After in 1 patient, the tested hemo-indicators have been normalizedwith MAOLO was not delayed and proceeded within schedule. After intake of SGN he chemotherapy was not delayed but the risk for complications remained high as a result of bone marrow toxicity registered after the chemotherapywith MAOLO as not delayed and proceeded within schedule. After intake of SGN he chemotherapy was not delayed but the risk for complications remained high as a result of bone marrow toxicity induced by the chemotherapyYordanovMammal gland carcinoma9 patients replacement was needed of SGN with during feeding3x2 feedingFor the patients with SGN, the hemoglobin fell below the lower limit.The chemotherapy after replacement with MAOLO continued within schedule.Mammal gland carcinoma9 patients replacement was needed of SGN with meded of SGN with toxicity after chemotherapy3x2 feedingFor the patients with SGN, the hemoglobin fell below the lower limit.The chemotherapy even not delayed, increased the risk for complications during feedingMammal gland carcinoma9 patients replacement was needed of SGN with meded of SGN with toxicity after chemotherapySkeFor the patients with SGN, the the lower limit.The chemotherapy even not delayed, increased the risk for complications during feeding <tr< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>ior t</td><td></td><td></td><td>1</td><td></td></tr<>								ior t			1	
center (COC)- Ruse- 2018 and Dr. Valerii Yordanovmonths - 10,11,12 2018 and Dr. Valerii Yordanovreplacement was needed of SGN with MAOLO (3x2c) due to bone marrow toxicity registered after the chemotherapyleucocytes, thrombocytes, hemoglobinAfter replacement of SGN with MAOLO in 1 patient, the tested hemo-indicators have been normalizedproceeded within schedule. After intake of SGN he chemotherapy was not delayed but the risk for complications remained high as a result of bone marrow toxicity induced by the chemotherapyWardanovMammal gland9 patients replacement was needed of SGN with MAOLO 3x2c due to bone marrow toxicity after chemotherapy3x2 capsules during feedingFor the patients with SGN, the hemoglobin fell below the lower limitThe chemotherapy after replacement with MAOLO continued within schedule.Mammal gland9 patients replacement was needed of SGN with during feeding3x2 capsules during feedingFor the patients with SGN, the hemoglobin fell below the lower limitThe chemotherapy after replacement with MAOLO continued within schedule.Mammal gland9 patients replacement was needed of SGN with MAOLO 3x2c due to bone marrow toxicity after chemotherapyfeeding feedingFor the patients with SGN, the hemoglobin, fell below the leucocytes are also below the lower limit.The chemotherapy even not delayed, increased the risk for complications due to bone marrow toxicity prevented by SGN at very low intensity.	-	•				-						
(COC)- Ruse- 2018 and EOOD Dr.10,11,12 2018 and EOOD Dr.needed of SGN with MAOLO (3x2c) due to bone marrow toxicity registered after the chemotherapythrombocytes, hemoglobinin 1 patient, the tested hemo-indicators have been normalizedintake of SGN he chemotherapy was not delayed but the risk for complications remained high as a result of bone marrow toxicity induced by the chemotherapyVordanovMammal gland9 patients replacement was toxicity after toxicity after chemotherapy3x2 feedingFor the patients with SGN, the hemoglobin, the lower limit.The chemotherapy after replacement with MAOLO continued within schedule.MAOLO 3x2c due to xicity after toxicity after chemotherapySx2 feedingFor the patients with SGN, the hemoglobin, the lower limit.The chemotherapy after replacement with MAOLO continued within schedule.Mammal carcinoma9 patients replacement was toxicity after chemotherapy3x2 feedingFor the patients with SGN, the hemoglobin, the lower limit.The chemotherapy even not delayed, increased the risk for complications due to bone marrow toxicity prevented by SGN at very low intensity.	e		carcinom	-		-						
Ruse- EOOD Dr. 2018 and 01.2019 MAOLO (3x2c) due to bone marrow toxicity registered after the chemotherapy hemoglobin have been normalized not delayed but the risk for complications remained high as a result of bone marrow toxicity induced by the chemotherapy Yordanov Mammal gland 9 patients 3x2 replacement was needed of SGN with to bone marrow toxicity after 3x2 capsules For the patients with SGN, the hemoglobin fell below the lower limit. The chemotherapy after replacement with MAOLO continued within Schedule. MAOLO (3x2c) due to bone marrow Mammal gland 9 patients 3x2 replacement was needed of SGN with to bone marrow For the patients with SGN, the hemoglobin fell below the lower limit. The chemotherapy after replacement with MAOLO continued within Schedule. MAOLO (3x2c) due to bone marrow feeding feeding After the intake of SGN, the the lower limit. After the intake of SGN, the chemotherapy even not delayed, increased the risk for complications due to bone marrow toxicity prevented by SGN at very low intensity.							•				-	
EOOD Dr. 01.2019 to bone marrow toxicity registered after the chemotherapy to bone marrow toxicity registered after the chemotherapy complications remained high as a result of bone marrow toxicity induced by the chemotherapy Yordanov Mammal gland 9 patients replacement was needed of SGN with to bone marrow toxicity after to bone marrow chemotherapy 3x2 carcinoma For the patients with SGN, the hemopoiesis is not essentially affected the lower limit The chemotherapy after replacement with MAOLO continued within schedule. MAOLO 3x2c due to bone marrow toxicity after chemotherapy feeding feeding After the intake of SGN, the hemopoiesis are also below the lower limit. After the intake of SGN with the leucocytes are also below the lower limit. out to bone marrow toxicity prevented by SGN at very low intensity.						0	•	ın	· ·			
Ivan Ivanov Ivan Ivanov toxicity registered of bone marrow toxicity induced by the chemotherapy Dr. Valerii after the chemotherapy chemotherapy Mammal 9 patients 3x2 For the patients with SGN, the The chemotherapy after replacement gland In 5 patients capsules carcinoma replacement was during needed of SGN with feeding feeding the lower limit After the intake of SGN, the In 1 patient, except for the hemoglobin, toxicity after increased the risk for complications toxicity after chemotherapy Imit. due to bone marrow toxicity prevented After replacement of SGN with by SGN at very low intensity. MAOLO, the hemo-indicators were					. ,		nemogiobili		have been no	illializeu		
Dr. Valerii Yordanov after the chemotherapy after the chemotherapy after the chemotherapy chemotherapy chemotherapy Mammal 9 patients 3x2 For the patients with SGN, the gland The chemotherapy after replacement gland In 5 patients capsules For 3 patients the hemoglobin fell below the lower limit With MAOLO continued within needed of SGN with feeding feeding After the intake of SGN, the After the intake of SGN, the In 1 patient, except for the hemoglobin, to bone marrow to bone marrow to bone marrow the leucocytes are also below the lower increased the risk for complications due to bone marrow toxicity after chemotherapy After replacement of SGN with by SGN at very low intensity.	·	01.2017										
YordanovMammal gland9 patients3x2Mammal gland9 patients3x2In 5 patients carcinomacapsulesreplacement was needed of SGN with to bone marrow toxicity after chemotherapyfeedingMAOLO 3x2c due to bone marrow toxicity after chemotherapyfeedingMAOLO 3x2c due to bone marrow toxicity after chemotherapyfeedingMAOLO 3x2c due to bone marrow toxicity after chemotherapyfeedingMAOLO, the hemo-indicators wereAfter replacement of SGN with the leucocytes are also below the lower limit.MAOLO, the hemo-indicators wereby SGN at very low intensity.	Dr. Valerii											• •
gland carcinomaIn 5 patients replacement was needed of SGN with to bone marrow toxicity after chemotherapycapsules during feedinghemopoiesis is not essentially affected For 3 patients the hemoglobin fell below the lower limitwith MAOLO continued within schedule.MAOLO 3x2c due to bone marrow toxicity after chemotherapyfeedingfeedingfeedingfeedingAfter replacement of SGN with MAOLO, the hemo-indicators werefeedingfeedingfeeding	Yordanov			che	notherapy							10
carcinomareplacement was needed of SGN with MAOLO 3x2c due to bone marrow toxicity after chemotherapyduring feedingFor 3 patients the hemoglobin fell below the lower limitSchedule.HereicherMAOLO 3x2c due to bone marrow toxicity after chemotherapyFor 3 patients the hemoglobin, the lower limitAfter the intake of SGN, the chemotherapy even not delayed, the leucocytes are also below the lower limit.After the intake of SGN, the chemotherapy even not delayed, the leucocytes are also below the lower limit.After replacement of SGN with MAOLO, the hemo-indicators wereSGN at very low intensity.			gland		patients	3x2			nemopoiesis is not essentially affected or 3 patients the hemoglobin fell below		with MAOLO continued within schedule.	
needed of SGN with MAOLO 3x2c due to bone marrow toxicity after chemotherapyfeedingthe lower limit the lower limitAfter the intake of SGN, the chemotherapy even not delayed, increased the risk for complications due to bone marrow toxicity prevented by SGN at very low intensity.After replacement of SGN with MAOLO, the hemo-indicators wereAfter replacement of SGN with by SGN at very low intensity.					•							
MAOLO 3x2c due to bone marrow toxicity after chemotherapy be an uncertainty of the leucocytes are also below the lower toxicity after chemotherapy be an uncertainty of the leucocytes are also below the lower limit. After replacement of SGN with MAOLO, the hemo-indicators were												
to bone marrow toxicity after chemotherapy to bone marrow toxicity after chemotherapy to bone marrow toxicity after chemotherapy toxicity after toxicity after chemotherapy toxicity after chemotherapy toxicity after toxicity after t						feeding		-				,
toxicity after toxicity after due to bone marrow toxicity prevented chemotherapy After replacement of SGN with by SGN at very low intensity. MAOLO, the hemo-indicators were MAOLO, the hemo-indicators were MAOLO									the leucocytes are also below the lower		increased the risk for complications	
chemotherapy After replacement of SGN with by SGN at very low intensity. MAOLO, the hemo-indicators were								the				
MAOLO, the hemo-indicators were					•					•		
					пошегару			ι			by Sorv at very low mensity.	

Table 1. Comparison between nutrient additive MAOLO and the product SGN.Summary of the results for nutrient additive MAOLO

The comparative study demonstrated that the product SGN does not possess the preventative, stimulating and normalizing effect on the hemopoiesis, as the original MAOLO. A conclusion can be drawn that the nutrient additive with the original name of MAOLO is efficient in the prevention of the bone marrow toxicity as a result of chemotherapy with hematoxic cytostatics by normalizing simultaneously and separately the observed hemo-indicators – leucocytes, thrombocytes and hemoglobin. In the statements of the clinical observations it has been noted that no unwanted drug reactions were found (even in treatment that lasted for 4-6 months) which are a result of the product application. The results display that the nutrient additive MAOLO prevents the use of expensive therapy with colon stimulating factors, transfusion of whole blood or thrombocyte mass aiming treatment of the cytotoxic complications and does not allow the interruption of te scheduled chemotherapy. Since MAOLO is a nutrient additive, the preclinical and clinical observations give better confidence to the doctors and patients that the product is with practically proven safety and efficacy as opposed to many other nutrient additives whereat such data is not known.

SofiaPrepared by: Chief Assistant Ivanka Kostadinova, PhD, signature20.11.2019Prof. Dr. Nikolay Danchev, MD, signature

Seal [MEDICAL UNIVERSITY, SOFIA, PHARMACEUTICAL FACULTY]